EUSA Pharma bolsters senior leadership team with two appointments
Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two newly-created roles: Dr Carsten Thiel as President Europe and Dr Darrel P Cohen as Head of Clinical Development.
In his new role, Dr Thiel will be responsible for leading EUSA’s growing commercial infrastructure in Europe. With a career boasting 27 years of commercial experience in the pharma industry, he has had stints at Alexion, where he led the company’s EMEA, Asia Pacific and Australasia organisations, and Amgen, where he headed up the company’s European oncology franchise before going on to become Head of Europe. Most recently, he served at gene therapy specialist Abeona Therapeutics as its CEO, until he was fired from the company in November 2018 for “personal misconduct” and “misconduct towards colleagues”, though exact details of this misconduct has never been revealed.
Remarking on his appointment, Dr Thiel said: “EUSA Pharma has made great progress building a strong oncology and rare disease business in just a few years, and I am honoured to lead the expansion of its commercialisation activities in Europe. The company has brought together a compelling portfolio, and I am excited at the prospect of helping EUSA achieve its ambitious plans for these specialist products.”
Meanwhile, Dr Cohen will take up leadership of EUSA’s worldwide late-stage clinical development operations. A haematologist and oncologist by background, his 20 years of clinical development experience in the industry has been built through his tenures at Sanofi-Aventis Oncology as Director of Clinical Research and Pharmacia Oncology as an Associate Director of Clinical Research. He was also a Haematology/Oncology Fellow and later an Associate in Medicine at Duke University Medical Center. He joins EUSA from Pfizer, where he was Vice President, Clinical Development Leader, while he also led clinical development functions for a range of products including Xalkori and Sutent.
“As an oncologist I have followed EUSA’s rapid development into a fully-fledged oncology and rare disease business, and I welcome this opportunity to contribute to the Company’s ongoing success as it expands its clinical development activities,” commented Dr Cohen. “Since acquiring the global rights to Sylvant at the start of the year the Company has the opportunity to significantly extend its use, in addition to further developing Qarziba, and I look forward to leading EUSA’s drive to make its innovative products available to as many patients as possible.”
Lee Morley, EUSA Pharma’s Chief Executive Officer, also commented on the twin appointments: “We are delighted to welcome Carsten and Darrel to EUSA. Both bring significant experience, vision and proven executional skills to the Company, which will prove invaluable as we continue the rapid expansion in Europe, emerging markets and the United States. With the ongoing commercial roll out of Fotivda in Europe and Qarziba and Sylvant globally, and the ramping up of development activities targeting a number of additional indications for Sylvant and Qarziba, we look forward to our new colleagues contributing to EUSA’s ongoing success.”
Efforts push on to discover an effective treatment for COVID-19 in more than 100 different …
EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …
EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications
Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …